The FDA has approved Takeda’s Orzeyful (oveporexton) for narcolepsy type 1 — the first medicine that targets the underlying cause of the disorder rather than just its symptoms.
Cleared on August 6, 2026, Orzeyful works by amplifying orexin-2, a brain protein that regulates wakefulness and alertness. People with narcolepsy type 1 lose the neurons that make orexin, so a drug that boosts orexin signaling addresses the root problem. In large trials it was significantly better than placebo at keeping patients awake and reduced the sudden muscle weakness (cataplexy) that defines the condition, and was generally well tolerated.
Not on shelves quite yet
Before launch, the U.S. Drug Enforcement Administration must complete a scheduling review, which can take up to 90 days.
A new, high-value class
Orzeyful opens what analysts see as a multibillion-dollar market for orexin-boosting drugs; Jefferies projects peak annual sales around $2 billion, with estimated pricing of $142,000–$250,000+ per patient a year. Rivals are close behind: Eisai has its own candidate, Eli Lilly bought Centessa Pharmaceuticals for $6.3 billion to enter the space, and Alkermes is testing alixorexton across narcolepsy and idiopathic hypersomnia. Being first gives Takeda a head start in a fast-emerging field.